FDA deadlines threaten drug safety

被引：0

作者：

不详

机构：

来源：

CHEMICAL & ENGINEERING NEWS | 2008年 / 86卷 / 14期

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Many drugs are approved against the deadline by FDA which might lead to unintended consequences with regard to drug safety. It is suggested that drug safety might improve under an FDA approval protocol that is more flexible and less driven by deadline pressures.

引用

页码：42 / 42

页数：1

共 50 条

[31] Post-market drug safety evidence sources: an analysis of FDA drug safety communications
Ishiguro, Chieko
Hall, Marni
Neyarapally, George A.
Dal Pan, Gerald
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 (10) : 1134 - 1136
[32] Post-marketing drug safety sources: An evaluation of the FDA's drug safety communications
Aldayel, Atheer
Alghamdi, Maha
Almutairi, Abdulaali
Al-Harbi, Fawaz F.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 302 - 302
[33] US FDA reports new steps in drug safety
Reactions Weekly, 2007, 1138 (1) : 3 - 3
[34] Bolstering the FDA's drug-safety authority
Schultz, William B.
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22): : 2217 - 2219
[35] FDA under pressure of address drug safety issues
Wechsler, J
BIOPHARM INTERNATIONAL, 2005, 18 (02) : 16 - 17
[36] FDA Sets Policies to Enhance Drug Security and Safety
Wechsler, Jill
BIOPHARM INTERNATIONAL, 2015, 28 (02) : 10 - 11
[37] Report on Drug Safety and the US FDA by the Institute of Medicine
Anthony W. Fox
International Journal of Pharmaceutical Medicine, 2006, 20 (5) : 289 - 291
[38] US FDA enhancing postmarketing drug safety surveillance
Reactions Weekly, 2019, 1780 (1) : 3 - 3
[39] Access and Safety-The FDA Drug Approval Conundrum
Good, Chester B.
Peasah, Samuel K.
JAMA NETWORK OPEN, 2024, 7 (07)
[40] US FDA 2009 drug safety warnings analysed
Reactions Weekly, 2012, 1388 (1) : 4 - 4

← 1 2 3 4 5 →